June 11, 2019
WELLESLEY, Mass., June 11, 2019–The growing prevalence of cancer and increases in funding for research are factors helping to drive the global tumor-specific antigen market, according to a report by BCC Research, “Global Tumor-specific Antigen Market.”
The market expects to see a compound annual growth rate (CAGR) of 6.2% through 2023, when it could be worth $2.4 billion.
Major players in the market include Go Therapeutics, Aivita Biomedical, Creative Diagnostics, Bio-Rad Laboratories (NYSE: BIO), Meso Scale Diagnostics and Merck Millipore (NYSE: MRK).
Research Highlights
“Tumor-specific antigen are substances that are produced in tumor cells,” notes report author Sathya Durga. “These substances trigger an immune response in the host. Tumor antigens are not membrane proteins. Instead, they are cytosolic protein derivatives. Tumor antigens are potential candidates for cancer therapy as these are beneficial tumor markers in the identification of tumor cells through diagnostic tests.”
Surge in Cancer Cases Seen as a Major Market Driver
A major market force is the surging numbers of cases of cancer, the report adds. Cases are particularly high in Central and Western Europe, while major cancer types include breast, colorectal, prostate, tracheal and bronchus. These factors are helping to drive investment in cancer diagnosis and research, with $41.3 million being invested in cancer research for biology in 2016, followed by $17.4 million for cause or etiology and $14.5 million for treatment research.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.
Global Tumor-specific Antigen Market( BIO184A )
Publish Date: May 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.